# Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

> **NCT00628251** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 97 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** AZD2281
- **DRUG:** Liposomal Doxorubicin
- **DRUG:** AZD2281

## Key facts

- **NCT ID:** NCT00628251
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-30
- **Primary completion:** 2009-09-15
- **Final completion:** 2018-09-19
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2019-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628251, "Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00628251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*